drugset
drugset / Trial / NCT06564467

A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JMT202

NCT06564467 ↗

Phase 1 Enrolling by invitation 54 enrolled Shanghai JMT-Bio Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JMT202 in Healthy Participants.

Timeline

Start
2024-07-23
Primary completion
2025-01-10
Completion
2025-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject JMT202 Unknown — Subcutaneous

Indications

No indication recorded.